Skribe Medical raised $1.65M in pre-seed funding led by SeaX Ventures, the San Francisco company said on November 11. GoAhead Ventures and Marin Sonoma Impact Ventures joined the round.
The Aurora system is a multi-sensor adhesive patch that estimates left ventricular ejection fraction with an AI model. Skribe is aiming it first at point of care checks during oncology visits, where watching for cardiotoxicity normally means booking an echocardiogram. Home monitoring is the longer-term goal.
The NOECHO study compares Aurora against echocardiography and has enrolled more than 800 patients across 10 US sites and one site in Southeast Asia. The FDA also selected Skribe for its READI-Home Innovation Challenge, which brings early agency feedback on home use design and is not a marketing authorization. Founders Ryan Neely, Josh Kay and Andrew Bohannon worked together at iota Biosciences. Eight hundred paired comparisons against echo is a large evidence base for a company at this stage, and it is the number that will decide the submission.